COMPANY:

MetaSight Diagnostics

"MetaSight Diagnostics...announced the closing of an $8 million oversubscribed Series A financing round. New investors include aMoon Growth II Fund, Saban Ventures, ARC Ventures and Alumni Ventures. Along with the continued support of existing shareholders, including aMoon's early-stage fund, aMoon Velocity, this investment enables MetaSight to advance its existing programs into FDA trials as well as expand its portfolio of diagnostic products....The company is currently in discussions with multiple strategic players regarding its lead programs MASH and CRC and is planning to make its tests available in selected markets in 2025."